1044-P: Advancing Quality Improvement Culture among 27 Pediatric and Adult Diabetes Centers

Abstract

Background: The T1D Exchange Quality Improvement Collaborative (T1DX-QI) is a learning health system of over fifty endocrinology centers working to improve diabetes outcomes through Quality Improvement (QI). Centers join T1DX-QI with varying levels of QI culture and are assigned a QI Coach to support practice transformation. This study summarizes the results of 27 endocrinology centers involved in the T1DX-QI for over 12 months. Method: Centers completed a 20-question self-assessment survey to measure QI culture over time in four evidence-based areas: QI Team Structure (team roles); QI Foundation (data collection and training); QI Capacity (use of QI tools); and QI Success (scaling up small tests). Data was collected in 2021 and 2022 for the same centers. The overall difference in QI Capacity was calculated using a Chi-Square test. Results: Overall, QI Culture increased from 67% to 75% from 2021 to 2022 (p-value = 0.005). Figure 1 demonstrates that improvements were seen in three of the four evidence-based areas for both pediatric and adult centers in this time. Conclusion: Even with as little as one year of involvement with the T1DX-QI, centers experience an improvement in their QI Capacity. Disclosure A.Mungmode: None. L.Chao: None. J.Ilkowitz: None. O.Ebekozien: Advisory Panel; Medtronic, Research Support; Eli Lilly and Company, Dexcom, Inc. T1dx-qi collaborative: n/a. O.Odugbesan: None. V.Elisha: None. D.W.Steenkamp: Research Support; Abbott Diabetes, Novo Nordisk. M.K.Kamboj: None. D.Desalvo: Consultant; Dexcom, Inc., Research Support; Insulet Corporation. R.Y.Sonabend: None. A.Neyman: None. P.M.Mathias: None. Funding The Leona M. and Harry B. Helmsley Charitable Trust